1. Home
  2. WINT vs BJDX Comparison

WINT vs BJDX Comparison

Compare WINT & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • BJDX
  • Stock Information
  • Founded
  • WINT 1992
  • BJDX 2015
  • Country
  • WINT United States
  • BJDX United States
  • Employees
  • WINT N/A
  • BJDX N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • BJDX Medical Specialities
  • Sector
  • WINT Health Care
  • BJDX Health Care
  • Exchange
  • WINT Nasdaq
  • BJDX Nasdaq
  • Market Cap
  • WINT 2.0M
  • BJDX 2.0M
  • IPO Year
  • WINT 1995
  • BJDX 2021
  • Fundamental
  • Price
  • WINT $0.12
  • BJDX $3.43
  • Analyst Decision
  • WINT Hold
  • BJDX
  • Analyst Count
  • WINT 1
  • BJDX 0
  • Target Price
  • WINT $7.00
  • BJDX N/A
  • AVG Volume (30 Days)
  • WINT 7.3M
  • BJDX 62.3K
  • Earning Date
  • WINT 11-27-2024
  • BJDX 03-27-2025
  • Dividend Yield
  • WINT N/A
  • BJDX N/A
  • EPS Growth
  • WINT N/A
  • BJDX N/A
  • EPS
  • WINT N/A
  • BJDX N/A
  • Revenue
  • WINT N/A
  • BJDX N/A
  • Revenue This Year
  • WINT N/A
  • BJDX N/A
  • Revenue Next Year
  • WINT N/A
  • BJDX N/A
  • P/E Ratio
  • WINT N/A
  • BJDX N/A
  • Revenue Growth
  • WINT N/A
  • BJDX N/A
  • 52 Week Low
  • WINT $0.11
  • BJDX $3.03
  • 52 Week High
  • WINT $14.75
  • BJDX $386.80
  • Technical
  • Relative Strength Index (RSI)
  • WINT 15.60
  • BJDX 46.53
  • Support Level
  • WINT $0.21
  • BJDX $3.41
  • Resistance Level
  • WINT $0.33
  • BJDX $4.22
  • Average True Range (ATR)
  • WINT 0.03
  • BJDX 0.36
  • MACD
  • WINT 0.00
  • BJDX -0.01
  • Stochastic Oscillator
  • WINT 2.15
  • BJDX 14.84

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About BJDX Bluejay Diagnostics Inc.

Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Share on Social Networks: